Dianna Shipley

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Howard A. Burris, F. Anthony Greco et al. · Journal of Clinical Oncology · 2011 · 160 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network

John D. Hainsworth, David R. Spigel, C. Farley et al. · Journal of Clinical Oncology · 2007 · 113 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer

John D. Hainsworth, David R. Spigel, C. Farley et al. · Cancer · 2007 · 70 citations

Medicine, Oncology, Pharmacotherapy +12

Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck

John D. Hainsworth, David R. Spigel, F. Anthony Greco et al. · The Cancer Journal · 2011 · 66 citations

Medicine, Oncology, Radiation Oncology +15

Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site

John D. Hainsworth, David R. Spigel, Bobby L. Clark et al. · The Cancer Journal · 2010 · 66 citations

Medicine, Oncology, Pharmacology +11